PDS Biotechnology (PDSB) Stock: Buy, Sell, or Hold?
PDSB - PDS Biotechnology Corporation Common Stock
$0.29
-0.02 (-6.47%)
âŧ
5d:
+34.05%
30d:
+21.86%
90d:
-73.67%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When PDSB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PDSB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PDSB is currently trading at $0.29, which is considered fair relative to its 30-day fair value range of $0.13 to $0.54.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.20, while resistance sits at $0.65. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: PDSB scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.75 (+1510.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PDSB is in a strong downtrend. Immediate support is located at $0.20, while resistance sits at $0.65. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: PDSB scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.75 (+1510.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.13 -
$0.54
Company Quality Score
40/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
39.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 1510.7% below Wall St target ($4.75)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.13 -
$0.54
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.20
Resistance Level
$0.65
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.81
Wall Street Target
$4.75
(+1510.7%)
Share & Embed Analysis
Last updated: September 13, 2026 1:01 PM ET
Data refreshes hourly during market hours. Next update: 2:01 PM
Data refreshes hourly during market hours. Next update: 2:01 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PDSB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$27 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
